Skip directly to content


Pristiq® belongs to a class of drugs called serotonin and norepinephrine reuptake inhibitors (SNRIs)1. SNRIs improve neurotransmission of two neurotransmitters, serotonin and norepinephrine in the brain, thereby improve the symptoms of mood problems1,2, suitable for those who are concerned with specific mood problems. In addition, Pristiq® is associated with lower potential for drug-drug interactions, especially in patients receiving comedications3,4,5. The once daily dosage1 provides better drug compliance.


  1. Pristiq® (desvenlafaxine) Prescribing Information. Pfizer Corporation Hong Kong Limited: version April 2018.
  2. Moret C and Briley M. The importance of norepinephrine in depression. Neuropsychiatric Disease and Treatment 2011:7(Suppl 1)9-13.
  3. Patroneva A, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Disp 2008; 36:2484-2491.
  4. Nichols AI, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-228.
  5. Low Y, et al. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatric disease and treatment 2018; 14:567.

[PP-CPF-HKG-0053] Sep 2019